[Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab]

Generalized pustular psoriasis (GPP) is often a life-threatening disease which, in contrast to psoriasis vulgaris, is associated with the formation of sterile pustules on the skin. Until recently, there was no approved treatment in Europe, so that drugs used for psoriasis vulgaris were also frequently used for GPP. However, new studies showed that, in GPP, mutation of the interleukin-36 receptor often leads to increased inflammation and corresponding disease activity. We report a case of GPP with complete remission after two doses of spesolimab, a new interleukin-36 receptor antibody.